Competitors Within
Home-grown smaller players are giving biggies a run for their money in the US generics market.
generics
November 2021
October 2019
September 2019
August 2018
Biocon’s biologics portfolio comes into its own
Bengaluru-based Biocon’s portfolio of biologic drugs has grown rapidly in the last five years and the company wants it to be a $1 billion business by 2022.
Healthcare spending to double by 2030: Bain report
Upper-middle-income households becoming the biggest demographic in 2030 will drive healthcare services.
The toughest period is behind us: Vinita Gupta
India’s third-largest generic drugmaker Lupin is focussing on building a pipeline of specialty drugs, while cutting costs and addressing regulatory concerns.
‘New complex generics to augur well for Lupin’
Vinita Gupta is confident that new complex generics, specialty drugs and manufacturing quality enhancement plan will augur well for the company
